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SUMMARY
Where very young children come into contact with water containing schistosome cercariae, infections occur and
schistosomiasis can be found. In high transmission environments, where mothers daily bathe their children with environ-
mentally drawn water, many infants and preschool-aged children have schistosomiasis. This ‘new’ burden, inclusive of co-
infections with Schistosoma haematobium and Schistosoma mansoni, is being formally explored as infected children are not
presently targeted to receive praziquantel (PZQ) within current preventive chemotherapy campaigns. Thus an important
PZQ treatment gap exists whereby infected children might wait up to 4–5 years before receiving ﬁrst treatment in school.
International treatment guidelines, set within national treatment platforms, are presently being modiﬁed to provide earlier
access to medication(s). Although detailed pharmacokinetic studies are needed, to facilitate pragmatic dosing in the ﬁeld, an
extended ‘dose pole’ has been devised and epidemiological monitoring has shown that administration of PZQ (40mg/kg), in
either crushed tablet or liquid suspension, is both safe and eﬀective in this younger age-class; drug eﬃcacy, however, against
S. mansoni appears to diminish after repeated rounds of treatment. Thus use of PZQ should be combined with appropriate
health education/water hygiene improvements for both child and mother to bring forth a more enduring solution.
Key words: Maternal and child health, preventive chemotherapy, dose pole, morbidity markers, faecal occult blood, GPS
dataloggers.
INTRODUCTION
In this review we outline past progress, current
evidence and new steps taken to control schistoso-
miasis in African infants and preschool-aged children
(PSAC). This evolving situation is set within the
context of preventive chemotherapy campaigns
which, during the last decade, have progressively
scaled-up operations to reach nationwide coverage
in several sub-Saharan countries (Savioli et al. 2009;
WHO, 2010). We also present some key epidemio-
logical ﬁndings from an ongoing prospective cohort
study of Ugandan children who have intestinal
schistosomiasis and are regularly receiving prazi-
quantel (PZQ) treatment(s).
Schistosomiasis and children
Control interventions targeted towards schistosomia-
sis, as presently recommended by WHO, have
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primary focus upon provision of free treatment with
PZQ to school-aged children (SAC), 5–14 years old,
as well as, adults (515 years old), who reside within
disease endemic regions (WHO 2006; Fenwick et al.
2009). Monitoring and evaluation (M&E) activities
undertaken to assess performance and impact of such
interventions – usually implemented by governmen-
tal authorities in the framework of their national
disease control programmes (NDCPs) – have shown
that over 17 million individuals were treated in 2008
(WHO, 2010), but have also revealed that children
aged 5 years and below – preschool-aged children
(PSAC, 1–5 years old) and infants (1–12 months
old) – can be commonly infected (Bosompem et al.
2004; Odogwu et al. 2006). Moreover, many are at
clear risk of developing overt disease and sadly these
children are almost invariably overlooked within
treatment campaigns. Therefore for some, their
disease-related morbidity and discomfort has not
been averted as quickly nor as successfully as
possible.
REDISCOVERY OF SCHISTOSOMIASIS IN
YOUNG CHILDREN
A singular and incomplete literature
It’s an old explorer’s adage that you only ﬁnd what
you are looking for and that, without considerable
pre-planning, ‘discoveries’ are not always as serendip-
itous as they ﬁrst seem. In the context of assessing the
occurrence and importance of schistosomiasis in the
younger child, whilst infections in infants and PSAC
had been noticed a long time ago (Smith, 1958; Perel
et al. 1985), it ﬁrmly fell oﬀ the radar of the medical
and scientiﬁc community as a topic of public health
importance until only recently. This was due to a
largely disjointed literature which was a collection of
sporadic reports failing to synergise as a whole and
promote the consequence of infections at an early age
(Woolhouse et al. 2000). It was noted, however, that
‘hyper-infections’ were possible causing the singular
death of a Brazilian PSAC where thousands of adult
worms were recovered at autopsy (Gryseels and de
Vlas, 1996).
Later, as the diagnostic methods then available
failed to ﬁnd egg-patent infections and ﬁeld epide-
miological studies reported that active water contact
rates, i.e. swimming and direct playing in water,
were generally low, it became widely believed that
infections were very rare in this younger age-
class (Jordan and Webbe, 1969). Furthermore, this
apparent lack of exposure became a pervasive argu-
ment, suﬃcient to result in categorisation of infants
and PSAC as largely free from disease unless
infection was taking place ‘in their back yard’
(Jordan and Webbe, 1969). During this period,
general interest rightly focused upon devising
urgent strategies to combat schistosomiasis in SAC
and adolescents, where it was becoming apparent
that in many places across sub-Saharan Africa,
infections were almost universal (Engels et al. 2002;
Bergquist, 2008).
From a research perspective, this aspect of disease
in young children was further subsumed by the
general focus upon schistosome-immunology and
vaccine development (Colley and Secor, 2007;
Bethony and Loukas, 2008), as well as the growing
excitement in exploring the parasite’s genome with
new molecular tools, which has started to come to
fruition (Webster et al. 2010). From a control
perspective, there were many changes too; with the
more aﬀordable price of PZQ as a public health tool
(Fenwick et al. 2003), international advocacy grew
(Hotez et al. 2007) and secured new ﬁnancial support
culminating in the release of major donor funds
which fostered the start-up and roll-out of several
NDCPs administering PZQ in preventive che-
motherapy, then later in integrated preventive
chemotherapy for neglected tropical diseases, to as
many SAC and adults as possible (Hotez et al. 2007;
Fenwick et al. 2009; Zhang et al. 2010).
A fresh focus on the younger child
The realisation that infection and disease were
occurring in children younger than school age started
to take form during discussions in London in May
2003, during the ﬁrst annual Schistosomiasis Control
Initiative (SCI) review meeting. There, it became
apparent that especially poor sanitation and water-
hygiene conditions abounded in several SCI-
supported countries, as exempliﬁed by images and
video footage within the “SCI Advocacy for Control
in Uganda” video and health CD (Beanland et al.
2006). The ﬁlm typiﬁed the remote and rural
conditions of high-transmission environments along
shoreline villages of lakes Albert and Victoria,
Uganda.
During this meeting, it was clearly shown that
infants and PSAC were being regularly bathed with
freshly drawn environmental water, either at the
water’s source or at home, which unmistakeably
pointed towards much more substantive levels of
water contact and exposure than previously thought.
This was also in accordance with the remarkably high
levels of disease prevalence (>75%) in schoolchildren
attending reception class (between 5–7 years old) in
Ugandan primary schools (Kabatereine et al. 2007),
which made it clear that a likely ‘PZQ treatment gap’
was occurring in PSAC, as conceptualised in the
schematic of Fig. 1.
This supposition of a treatment gap occurring was
later conﬁrmed by ad hoc epidemiological surveys of
PSAC in Uganda and Ghana using more sensitive
diagnostic methods (Bosompem et al. 2004; Odogwu
et al. 2006).
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DEFINING THE ‘PZQ TREATMENT GAP ’
Building a new epidemiological synthesis
The evidence provided by Bosompem et al. (2004)
and Odogwu et al. (2006) clearly showed that
children under 3 years of age were at substantial
risk of urinary or intestinal schistosomiasis, with a
surprisingly large proportion already having egg-
patent infections. Moreover, these infections were
most likely not acquired by active water contact of the
child but rather by passive exposure(s) to water
containing schistosome cercariae owing to the bath-
ing and water-drawing practices of their mothers/
guardians. This was clearly aﬃrmed byOdogwu et al.
(2006) who interviewed mothers of the children with
a semi-structured water contact questionnaire.
Attempting to draw a new epidemiological apprai-
sal, the article by Stothard and Gabrielli (2007a)
was the ﬁrst provocative attempt to highlight the
importance of schistosomiasis in the younger child
and this ‘PZQ treatment gap’, set within the context
of preventive chemotherapy and NDCPs. It reported
on the present inequality of health care provision
and outlined some steps that needed to be undertaken
to move towards inclusion of younger children
within disease control strategies. Foremost was to
foster inter-sectoral collaborations with other stake-
holders committed to maternal and child health.
The article stimulated some debate and points raised
by Johansen et al. (2007) were formally discussed
by in a reply by Stothard and Gabrielli (2007a).
The conclusion drawn was that formal inclusion
of younger children in treatment campaigns was
warranted, along with further thematic research
necessary to optimise interventions and ensure safety
(Johansen et al. 2007; Stothard and Gabrielli,
2007a,b).
There have been several other reports investigating
the occurrence of schistosomiasis in younger children
across sub-SaharanAfrica (Maﬁana et al. 2003; Opara
et al. 2007; Sousa-Figueiredo et al. 2008; Stothard
et al. 2008; LaBeaud et al. 2009; Chu et al. 2010;
Ekpo et al. 2010; Garba et al. 2010; Dabo et al.
2011; Namwanje et al. 2011; Verani et al. 2011).
A particularly disturbing report of which is by
Garba et al. (2010) documenting thatS. haematobium
and S. mansoni co-infections are common among
very young children in Niger. Alarmingly, in certain
mixed-species transmission foci inMali, for example,
very young children have overt morbidity of the
bladder, ureters and kidneys as detectable upon
ultrasonography (M. Sacko, unpublished data).
These observations on co-infection clearly open up
another avenue of research detailing how young
children respond to each parasite separately, or in
combination, potentially revealing any interactions
through time. Such early infections are also likely of
consequence in modulating response to routine
vaccination (LaBeaud et al. 2009).
The importance of early treatment with PZQ
Schistosomiasis in infants and PSAC is of concern for
at least two reasons. First, this younger age-group
plays a hitherto unrealised role in helping to maintain
local disease transmission; even though these infected
children may be excreting fewer eggs, it is their
regular water contact that leads to contamination of
water. Moreover, rinsing and washing children’s
soiled clothes in environmental water bodies also
contributes towards more cryptic contamination and
disease transmission (Stothard and Gabrielli, 2007a).
Thus this age-group might well play an increasingly
important role in environmental transmission likely
to frustrate the attempts made by preventive che-
motherapy campaigns striving towards more general
reductions in environmental transmission (King et al.
2006; French et al. 2010). Second, such regular water
contact is also likely to result in frequent (re)infection
Fig. 1. Schematic depiction of the ‘PZQ treatment gap’ in young children for schistosomiasis which can typically be
between 1 and 4 years. The red bar gradient depicts a possible timeline of duration of infection and disease progression
(A) and the open question of when a child should receive ﬁrst treatment within this timeline is raised (B). Upon entry
into the primary school system, children aged 5–6 years usually receive ﬁrst treatment of 1 tablet of PZQ (i.e. 40mg/kg
dose) although much younger children are known to be infected before entry into formal schooling. Indeed, the age of
ﬁrst infection can be within the ﬁrst year and for some the ‘PZQ treatment gap’ may be up to 5 years in duration.
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episodes, which lead to a progressive increase of
individual worm burden. It is therefore likely that
untreated infections acquired in early childhood
contribute to worsening the longer-term clinical
picture of disease in the individual (Stothard et al.
2011a).
Both reasons call for a more inclusive approach to
control of schistosomiasis. Of note is an additional
consideration that younger children, being smaller,
will require fewer tablets of PZQ than their older
counter-parts, and therefore treatment initiatives
targeting the younger child could be cheaper, in
terms of drug procurement, and achieve promising
future returns in reduction of both morbidity and
transmission (Hotez et al. 2010; Sousa-Figueiredo
et al. 2010a).
ADMINISTRATION OF PZQ IN THE
YOUNGER CHILD
Problems in the administration of PZQ to very young
children became evident in the context of a pilot
programme targeting the under-ﬁves in Ugandan
shoreline villages of lakes Albert and Victoria
conducted in 2006 (Stothard et al. 2008) and 2009
as reported by Sousa-Figueiredo et al. (2010b). The
rationale of this intervention was that parasitological
surveys using more sensitive diagnostic techniques of
worm-antigen and host-antibody detection, had
revealed the common occurrence of schistosomiasis
infection and disease in infants and PSAC living in
this area. This was further evidence of this age-class
was playing a stable role in endemic disease trans-
mission. Thus it was deemed necessary to expand the
NDCP’s treatment remit in these areas, even in the
absence of pharmacokinetic evidence, and provide
these infected children with treatment as not to do so
was considered unethical (Johansen et al. 2007).
An extended PZQ ‘dose pole’
As these shoreline environments are typical resource-
poor settings, the availability of reliable weighing
scales was constrained and a limiting factor in a
public health setting (Sousa-Figueiredo et al. 2010b).
Therefore, a PZQ ‘dose pole’ was needed similar to
that used in treatment of SAC (Montresor et al. 2001,
2002). However, the existing WHO height pole’s
lowest height division is 94 cm (above which a single
600mg-tablet is recommended) and this lower
threshold was too-high to cover the typical stature
range of infants and PSAC. An extended pole was
therefore developed based upon height and weight
data from several hundred Ugandan children (Sousa-
Figueiredo et al. 2010b). This formative data set was
later added to with additional child height-weight
(n=2183) information obtained from elsewhere
(Angola, Mali, Sudan and Zimbabwe) permittingT
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an experimental validation of this extended ‘dose
pole’ in locations outside Uganda (see Table 1;
Sousa-Figueiredo et al. 2010b).
In amending the PZQ dose pole, two new height
intervals were added at the bottom to extend the
PZQ treatment pole downwards: 84–99 cm for three-
quarters tablet and 60–84 cm for one-half tablet
(Sousa-Figueiredo et al. 2010b). Based on statistical
analysis, the current WHO pole’s single table lower
limit threshold was upwardly adjusted to 99 cm
from 94 cm which facilitated better dosing in this
height-weight range. This extended PZQ ‘dose pole’
was initially proven satisfactory in Uganda as well as
experimentally on a population of children from
Zanzibar, United Republic of Tanzania (prevalence
levels of acceptable dosages, between 30–60mg/kg,
estimated were 98·6% and 97·6%, respectively). The
later cross-country evaluation conﬁrmed a broader
applicability of this extended ‘dose pole’ (see
Table 1). Visual inspection of Fig. 2B reveals that its
Fig. 2. Creating and applying the newly extended PZQ ‘dose pole’ for more rapid dosing of PSAC (1–4 year olds) with
the distribution of height and weight measurements from children from: Uganda – ‘genesis’ population n=1046, ‘same
villages’ population n=1047, ‘diﬀerent villages’ population n=1210, ‘syrup trial’ population n=981; Angola (n=1067);
Mali (n=405); Sudan (n=137); Zanzibar (n=470) and Zimbabwe (n=104) with a polynomial model was ﬁtted to
validate information for ‘genesis’ population (A). The distribution of PZQ dosages that would have been given to
Ugandan, Malian, Sudanese, Zanzibari and Zimbabwean children if height had been used to predict weight from this
extended ‘dose pole’ (B). Grey transparent rectangle highlights the range of children who would have received an
acceptable PZQ dose (30 to 60mg/kg) (see Montresor et al. 2005). Some of these data have been presented elsewhere
(see Fig. 3A & B of Sousa-Figueiredo et al. (2010b)).
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performance is acceptable in providing 30–60mg/kg
dose of PZQ in the sampled population.
Concerning the height-weight data collected
during a trial of PZQ syrup in Uganda (Table 1)
with the aim of assessing the feasibility of provision of
liquid formulation of PZQ, it is interesting to note
that a poorly serviced set of weighing scales from a
local health centre was used for dosing rather than the
extended ‘dose pole’. It is clear that the use of these
scales generated more severe errors in dosing than the
extended dose pole would have introduced. As dose
poles are ﬁxed in length and largely immutable, they
are much less likely to suﬀer from such subsequent
systematic bias. The unreliability of weighing scales
when kept in such resource-poor settings, their
potential for de-calibration or malfunction, as well
as, the longer time taken to weigh a child (often in
conjunction with the mother/guardian holding)
suggest that this dosing approach is not pragmatic
enough for preventive chemotherapy campaigns.
By contrast, ‘dose poles’ oﬀer a more appropriate
approach especially when large numbers of children
are to be targeted (Montresor et al. 2001, 2002;
Sousa-Figueiredo et al. 2010a).
PZQ formulations: crushed tablets or
liquid suspensions?
Owing to concerns in using PZQ in children younger
than school age (Johansen et al. 2007; Stothard and
Gabrielli, 2007a,b), even though the safety and
tolerance of this drug in older children is excellent
(Utzinger and Keiser, 2004; Doenhoﬀ et al. 2009),
Sousa-Figueiredo et al. (2010b) documented more
formally the operational conditions and concerns of
preventive chemotherapy with PZQ in this resource-
poor setting. Given the diﬃculties of younger
children swallowing large PZQ tablets, and an
associated risk of choking, medications were admin-
istered in crushed tablet form and mixed with
orange-syrup as previously piloted by Odogwu
et al. (2006). The latter fruit ﬂavour helped to mask
the bitter taste of PZQ (Meyer et al. 2009), although
some children fail to recognize the unusual taste of
PZQ, thus the suspension could be spoon-fed to the
child by its mother under supervision of an attending
nurse, without any rejection or rarely with compli-
cation (Sousa-Figueiredo et al. 2010b).
In addition, as post-treatment side-eﬀects of PZQ
in SAC are known (Utzinger and Keiser, 2004;
Doenhoﬀ et al. 2009) and that as PZQwas being used
in an oﬀ-label use in this setting, Sousa-Figueiredo
et al. (2010b) monitored the occurrence of putative
side-eﬀects and eﬃcacy of crushed tablet PZQ
treatment. Adverse events and putative side-eﬀects
were ascertained by interviewing the mothers (they
themselves were treated during the surveys) who then
also monitored the welfare of their children at home.
Children were then re-examined the following day
after treatment along with their mothers attending.
Table 2. A comparison of the performance of PZQ, in either crushed tablet or syrup suspension, for the
treatment of intestinal schistosomiasis in Ugandan children aged46 years and also against those who were
either treatment-naive or a prior treatment history of up to three times during the previous year. Diagnosis
of infection status was by duplicate smear Kato-Katz technique on two consecutive day stools on ﬁrst day of
the treatment comparison then at 21 or 28-days later
Treatment-naive populations Treatment-exposed
populations
Pilot studyA
Syrup study
(syrup)B
Syrup study
(crushed tablet)B
Treatment
studyC SIMI cohortC
No. of day for follow-up 21 21 21 28 28
No. of children at
baseline
28 105 116 104 88
No. of children positive
on follow-up
0 19 23 44 66
Mean intensity at
baseline (EPG)
28·4 301 348·6 448·6 317·5
Mean intensity on
follow-up (EPG)
0 36·4 40·2 64·9 84·3
Cure rate% (95% CI)* 100·0 81·9 80·2 57·7 25·0
(87·7–100·0) (73·2–88·7) (71·7–87·0) (47·6–67·3) (16·3–35·4)
Egg reduction rate%
(95% CI)□
100·0 87·9 88·5 85·5 73·5
(87·7–100) (83·8–91·5) (84·7–91·7) (81·9–88·6) (68·3–78·3)
A This took place in Lake Victoria villages in February 2008; B These studies took place in Lake Albert villages in July
2010; C These studies took place in diﬀerent Lake Albert villages in July 2010 to B; * Cure rate is deﬁned as the percentage
of the infected population negative for infection after drug treatment; □ Egg reduction rate is deﬁned as the percentage
reduction in faecal EPG infection intensity as measured after treatment follow-up.
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Side-eﬀects were mild in nature, e.g. vomiting,
fatigue, vertigo and abdominal cramps, and typically
resolved by 24 hours after treatment.
As an additional observation, Sousa-Figueiredo
et al. (2010b) further monitored a selection of
children in a pilot study 21 days after ﬁrst treatment
ﬁnding that reported symptoms had reverted to levels
at baseline. At this 21-day inspection in villages on
the shoreline of Lake Victoria, the parasitological
cure rate of 28 previously egg-patent children was
found to be 100% (see Table 2). This was initial
evidence that the concerns of poor parasitological and
pharmacological performance of PZQ within this age
class were unfounded.
With increasing interest in whether PSAC should
be provided with access to PZQ, in 2010, WHO
commissioned across-country study (seeMutapi et al.
2011) in the use of liquid suspension, or syrup
formulation of PZQ as an alternative to use of crushed
or broken tablets. It should be noted that the ‘syrup’
formulation, however,doesnotmask thebitter taste of
PZQ. The results of this treatment comparison in
terms of parasitological performance are shown in
Table 2, with broader ﬁndings to be published
elsewhere. In total, over 100 children in each treat-
ment arm (syrup (n=105) versus crushed tablets
(n=116)) were examined to ﬁnd that the formulations
were broadly equivalent in terms of cure rates, egg
Fig. 3. Treatment clearance comparisons between treatment-naive and treatment-exposed preschool-age population
cohorts with a graphical representation of individual responses: naïve (n=104) and exposed (n=88), the latter had
started to receive treatment in the previous year and at 3 and 6 months prior. Each individual is represented by a line
which starts at the individual’s initial egg count (eggs per gram of stool –EPG) and ends at their egg count 21 days after
treatment. The graph to the right zooms in to the ranges 0 to 800 EPG to give more detail at this ﬁner scale. The
numbers to the right indicate the number of individuals whose EPG rose (arrow pointing up), decreased not reaching
zero (arrow point down), decreased to zero or cleared (arrow pointing to zero) and those that remained with the same
intensity (±24 EPG).
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reduction rates and recorded side-eﬀects (data not
shown) as reported in Table 2. It is interesting to note
that the cure rate in this LakeAlbert setting was lower
that that previously found in Lake Victoria.
Overall, crushed tablets provide a more pragmatic
alternative as tablets are more widely available within
sub-Saharan Africa than syrup-based formulations.
Moreover, owing to costs of transportation and
logistics, syrup-based formulation of paediatric
drugs are being advocated less and less by WHO,
which is now broadly favouring medications in
dispersible tablet formulation which are, however,
presently not available for PZQ (L. Chitsulo,
personal communication). This is also important
for keeping the costs of drug-shipping and distri-
bution as streamlined as possible. Crushed or broken
tablets provide an immediate way forward but as a
desirable reﬁnement, future PZQ tablets should be
manufactured with markings to allow easier division
into four quarters than the present half tablet
divisions. This is particularly important for more
precise dose estimation when treating children
weighing between 7·5 and 11·25 kg who need a
three-quarters tablet. Looking further into the
future, attempts of making PZQ more palatable, i.e.
exclusion of the inactive isomer that gives the drug a
bitter taste (Utzinger and Keiser, 2004; Meyer et al.
2009; Doenhoﬀ et al. 2009), should be pursued
perhaps as well as tablet coatings or linings (Sousa-
Figueiredo et al. 2010b).
ONGOING OPERATIONAL RESEARCH IN UGANDA
With funding from the Wellcome Trust, a 4-year
project was established in November 2008 with the
intention of developing a national treatment platform
in Uganda for treatment of infants and PSAC.
The project was also to gather new epidemiological
information on the performance of PZQ in reducing
intestinal schistosomiasis and was set within a
prospective cohort study of some 1200 infants and
PSAC (Stothard et al. 2011a).
Regular treatment and changes in
parasitological eﬃcacy
Until recently, the parasitological performance of
PZQ in the younger child was not known, concurrent
with the general lack of formal documentation and
pharmacokinetics of this drug in its use in infants and
PSAC (Stothard and Gabrielli, 2007a,b). More
broadly, there are general concerns on the perform-
ance of this drug against S. mansoni with reports on
occurrence of treatment failures or the necessity of
immune-mediated killing mechanisms of adult
Fig. 4. Image of child with obvious visual signs of intestinal schistosomiasis (A) but likely also has more cryptic bowel
pathology which is often not noticed without investigative surgery. To illustrate, in animal models the pathology of the
bowel from schistosome granulomas can be extreme as seen in (B) or more so when the intestine is removed (C), the
black arrow denotes approximately the same part of the bowel. Not only do such lesions likely lead to malabsorption but
also lack of peristalsis. Infection in infancy and early childhood likely leads to development of serious disease even before
adolescence.
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worms, which is thought to synergise with PZQ-
induced damage to the worm tegument (Doenhoﬀ
et al. 2009).
Using new and unpublished information, Table 2
summarises the present knowledge of drug perform-
ance within this age-class in Uganda for S. mansoni
during these ongoing M&E studies. Overall, the cure
rates appear reasonable but of most concern is the
lower cure rate of 25% in children with history of
previous PZQ treatment over the course of a year.
This lower cure rate could simply be the consequence
of selection: children who harbour either more PZQ-
tolerant worm populations or are only able tomount a
partial immune-mediate killing response to adult
worms (Doenhoﬀ et al. 2009). The drug clearance
curves by individuals are particularly insightful in
this light in that there are individuals who do not
appear to ‘clear’ infection, or rather, the level of
excreted eggs actually increases (Fig. 3). This is
especially important in context of stationarity of
prevalence of schistosomiasis in the prospective
cohort (see below). As a plausible alternative it
could also result from subtle adaptive responses of
adult worms to become more resilient or repair more
quickly the tegumental damage induced by PZQ
(Doenhoﬀ et al. 2009). Greater scrutiny of the natural
Fig. 5. Longitudinal dynamics of the general prevalence (%) of antigen excretion in urine (CCA test), egg excretion in
stool (Kato-Katz) and antibody response to eggs (SEA-ELISA) in Ugandan children aged46 years living in Lakes
Albert (A) and Victoria (B) are rather stationary. Note: all children received PZQ treatment at baseline; then selective
treatment undertaken at 3 months (positive by CCA test), at 6 months (positive by CCA test or Kato-Katz) and then
mass treatment again given out at 12 months; no data were collected at 9 months. The graphs show that even with
regular access to PZQ, intestinal schistosomiasis abounds within this study cohort.
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diversity, changes in worm tegument and its dynamic
turnover could be particularly insightful in the
context of PZQ induced changes.
Morbidity markers: faecal calprotectin and occult blood
As with general thematic research on schistosomiasis,
the search for ﬁeld-applicable markers of morbidity
continues (Webster et al. 2009). In the context of the
younger child, this is particularly important as using
such markers could help develop a better under-
standing of an individual’s progression from initial
infection through to acute or chronic stages of this
disease. It would be hoped also that after PZQ
medication(s), morbidity will be arrested, with
reversion, following from reduction(s) in worm
burdens (Betson et al. 2010). It is particularly dis-
appointing that the repertoire of morbidity marker
assays is meagre such that whilst SAC can have
obvious visual signs of severe disease, for example
that the child shown in Fig. 4a who has obvious
hepatosplenomegaly and likely has granulomatous
masses or ‘bilharzomas’ around the bowel (the latter
exempliﬁed in Fig. 4b and 4c within a laboratory
animal) it is not possible to document this precisely
without recourse to surgery.
In search of new markers of bowel morbidity,
Betson et al. (2010) determined whether faecal
calprotectin or faecal occult blood (FOB) assays
could be used as morbidity indicators for intestinal
schistosomiasis. They examined a cohort of 1327
PSAC and 726mothers in Uganda in which the prev-
alence of egg-patent infection was 27·2% in children
and 47·6% in mothers. No association was found
between infection and faecal calprotectin in children
(odds ratio (OR)=1·08; P=0·881), however, an in-
verse relationship (OR=0·17;P=0·043) was found in
mothers. By contrast FOB was strongly associated
withS.mansoni infection in both children (OR=2·30;
P<0·001) and mothers (OR=1·95; P=0·004)
suggesting that FOB testing was capturing some
aspects of bowel morbidity associated with schistoso-
miasis as eggs perforate the bowel triggering a small
release of blood into the intestinal lumen (Betson et al.
2010). Using these same data but classifying infection
status on the basis of host antibodies to schistosome
soluble egg antigen (SEA), an association between
FOB and infection was still apparent (data not
shown). In future, it will be interesting to ascertain
how FOB levels change during the course of ongoing
treatment with PZQ though it presently remains to be
explained what are the causal factor(s) leading to the
occurrence of FOB in those without schistosomiasis.
Impact of PZQ treatment on prevalence
and organomegaly
Over the course of two years, the prospective study
cohort has also been inspected for levels of anaemia,T
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splenomegaly and hepatomegaly, alongside diagnosis
and treatment for malaria and soil-transmitted
helminthiasis. Table 3 records the overall changes
in the status of each variable at baseline and at follow-
ups. Whilst general levels of prevalence of schistoso-
miasis have broadly shown stationarity during the
course of these follow-up (see Fig. 3), there are some
encouraging trends of morbidity reversion. For
example, the decrease in FOB from 22·4% to 15·7%
is of note potentially conﬁrming the future use of
FOB tests as markers of morbidity dynamics in the
face of treatment. At the same time, the highly
signiﬁcant reductions of anaemia in this cohort are
perhaps most likely due to the management of
malaria with artemisinin-based combination therapy
(ACT). Further multivariate analysis of these data
and organomegaly statistics is ongoing and will be
later reported in the fuller context of this longitudinal
cohort study.
Spatial micro-epidemiology and behavioural risks
It is clear that young children are infected with
schistosomes largely depending on how, when and
where their mothers draw water for domestic use and
child-bathing practices. To shed detailed light on this
aspect of water contact, Seto et al. (unpublished data)
have used small global positioning system (GPS)
dataloggers (Paz-Soldan et al. 2010; Stothard et al.
2011b) to record the movements of both mother and
child pairs and their likely duration of exposure
during a typical 3-day period. Analysis of these
spatial patterns has provided a diﬀerent insight into
the social networks that exist between mother and
child on the day-to-day level. For example, mothers
spend on average more time (137min) on the
immediate lake shore, or the exposure zone, than
their PSAC (112min).
Of the mothers’ time spent on the immediate lake
shoreline, on average 15min appear to have been
spent interacting with other mothers, while 25min
were spent interacting with their PSAC. On the other
hand, PSAC often spent time with other similar-aged
children (34min) on the lake shoreline. Fig. 6
attempts to illustrate that the locations of social
interactions on the lake shoreline which are, in fact,
quite spatially concentrated rather than dispersed
across the shore. This suggests that not only can such
wearable GPS-dataloggers be used to pinpoint the
locations at which exposures occur, but also where
social interactions are involved with water contact
and putative exposure, locating times and places
for future social-behavioural studies to help under-
stand the local transmission biology for these younger
children and perhaps devise appropriate interven-
tions (Stothard et al. 2011a).
TOWARDS CHANGES IN INTERNATIONAL
GUIDELINES
Given the potential scale of the problem of schisto-
somiasis in infants and PSAC across sub-Saharan
Fig. 6. Local map of Bugoigo village on the shoreline of Lake Albert, Uganda with the GPS tracks of mothers and
children overlaid across the map. The tracks were downloaded from GPS-dataloggers attached to the participant’s wrist
over a 3-day period. The red kernel and black kernel correspond to geographical locations of where most social
interactions took place during the same time across the 3-day period. An important future consideration is to devise best
ways to mitigate water contact within this mother and child group yet allowing them to undergo their daily tasks.
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Africa, a key challenge will be to gauge more pre-
cisely the total numbers of children living in need
of treatment (Engels and Savioli, 2009; Utzinger
et al. 2009). Without question, it is likely to be in
the region of several millions, possibly even an order
of magnitude higher; while a clear relationship
between infection levels in SAC and PSAC has
not been established yet, it is likely that the
geographical distribution of PSAC at-risk will be
largely restricted to the zones where general disease
transmission is very high, for example, in areas
where pre-NDCP prevalence in SAC is well in excess
of 50%. Developing algorithms to delineate and
strategically target such locations will become ever
more important especially as control is rolled out
reaching remoter areas where disease surveillance
has been poor or previously lacking (Stothard et al.
2011a,b).
There will of course be some quicker geographical
ﬁxes than others, especially where the local epide-
miological landscape is relatively simple, such as the
transmission landscapes of the Great East Africa
Lakes. In these areas, zones of intervention could
largely be deﬁned as fringing paths, or swaths, which
track the immediate lake shoreline up to 1 km
inland in which infants and PSAC will have likely
had regular exposure to water containing schisto-
some cercariae. In future, epidemiological surveys
should bring together household mapping technol-
ogies and remote sensing imagery, in the form of
clear-cut intervention maps that are easily under-
stood by politicians, health stakeholders and the
receipts of control themselves (Dabo et al. 2011;
Mutapi et al. 2011; Stothard et al. 2011a; Verani et al.
2011).
Tomove forward in a concerted manner, especially
when several countries have to decide their own best
course of actions, a revision of WHO guidelines will
facilitate this move. In September 2010, an informal
2-day meeting took place at Geneva which brought
together new evidence from several countries con-
cerning the occurrence of schistosomiasis in the
younger child as well as the performance of PZQ
treatment for encouraging changes in its formal
licensing or oﬀ-label use in treatment of young
children. The outcomes from this meeting will be
reported elsewhere as well as the advocating the need
for pharmacokinetic studies (Keiser et al. 2011), but
it is ﬁrmly assured that exciting progress will follow
triggered by these ﬁrst few steps within this
international forum.
CONCLUSION: CLOSING THE ‘PZQ
TREATMENT GAP ’ ?
Treatment of younger children with PZQ is ethically
warranted, proven to be safe and can be implemented
successfully on the ground in the frame of preventive
chemotherapy. Progressive scale-up of control, in
areas of high endemicity, towards acceptance at the
national level is now needed alongside changes in
international guidelines and political commitment.
If the above steps are taken and pharmacokinetic
studies assist to further optimise pragmatic dosing,
this PZQ treatment gap could be closed within the
foreseeable future. By giving infants and PSAC
access to medication this should lead to real progress
in the management of paediatric schistosomiasis in
the public health setting.
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